Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0178874 (tumor progression)
 40,807 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 78-year-old woman with advanced HCC had been treated by transarterial chemoembolization with epirubicin, however, tumor progression was not controlled and a tumor thrombus was found in the portal vein trunk. A new treatment method for transarterial chemoembolization using CDDP with DSM and SAP-MS was introduced. Marked regression of hepatic lesions and portal vein tumor thrombus was observed after two sessions. No adverse effect was found. The patient has been controlled without tumor recurrence and elevation of tumor marker for 14 months. A new treatment protocol will be useful for patients with far advanced hepatocellular carcinoma with portal vein tumor thrombus.
 ...
PMID:[A case of advanced hepatocellular carcinoma with tumor thrombus treated by transarterial chemoembolization therapy using cisplatin (CDDP) with DSM and SAP-MS]. 1622 53

Cytotoxic chemotherapy is ineffective in metastatic renal cancer. However, systemic administration of interleukin 2 (IL-2) or infusion of dendritic cells (DCs) loaded with tumor extracts can lead to some response rates with concomitant survival improvements. We report the results of a phase I-II pilot study combining DCs and IL-2 where six patients were included. DCs were derived from bone marrow CD34+ cells and loaded with autologous tumor extracts. CD34-DC vaccines were infused subcutaneously at day 45, 52, 59, 90 and 120 following surgery in combination with IL-2, that was subsequently administrated after the 3rd and 4th DC vaccinations. Preparation of tumor extracts and CD34-DCs were satisfactory in all patients but one. Due to rapid tumor progression, one patient was excluded before vaccination. In the 4 remaining patients, two received 3 vaccinations, while the 2 others received 5 vaccinations and the full IL-2 treatment. No adverse effect due to the vaccinations was observed. A specific immune response against autologous tumor cells was observed in the 2 patients who completed the treatment. Interestingly, these 2 patients had a more prolonged survival than the patients receiving 3 vaccinations. Importantly, a transient and massive increase of circulating natural regulatory T-cells (nTregs) was evidenced in 3 patients following IL-2 administration. Overall, the use of CD34-DC vaccines is feasible, safe and non-toxic. A specific anti-tumor immune response can be detected. However, our data highlights that IL-2 is a potent inducer of nTregs in vivo and as such may have a negative impact on cancer immunotherapy.
 ...
PMID:Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. 1963 77